Skip to main content
. 2021 Jul 9;18(4):2458–2467. doi: 10.1007/s13311-021-01084-9

Table 1.

Baseline characteristics of matched HSV and control cohorts

HSV subjects (n = 87,687) Controls (n = 217,895) SMD
Sex
  Female 5794 (6.6%) 11,863 (5.4%) 4.9
  Male 81,893 (93.4%) 206,032 (94.6%) 4.9
Race
  (Missing) 2944 (3.4%) 7438 (3.4%) 0.3
  Black 16,513 (18.8%) 40,623 (18.6%) 0.5
  Other 3988 (4.5%) 8571 (3.9%) 3.0
  White 64,242 (73.3%) 161,263 (74.0%) 1.7
Age
  50–59 37,693 (43.0%) 92,043 (42.2%) 1.5
  60–69 32,152 (36.7%) 81,170 (37.3%) 1.2
  70–79 12,911 (14.7%) 32,838 (15.1%) 1.0
  80 +  4931 (5.6%) 11,844 (5.4%) 0.8
Rurality
  (Missing) 133 (0.2%) 305 (0.1%) 0.3
  Rural and highly rural 28,196 (32.2%) 79,047 (36.3%) 8.7
  Urban 59,358 (67.7%) 138,543 (63.6%) 8.7
Priority
  (Missing) 16 (0.0%) 39 (0.0%) 0.0
  Level 1 11,694 (13.3%) 27,793 (12.8%) 1.7
  Level 2 5309 (6.1%) 13,128 (6.0%) 0.1
  Level 3 9981 (11.4%) 25,139 (11.5%) 0.5
  Level 4 242 (0.3%) 484 (0.2%) 1.1
  Level 5 23,983 (27.4%) 59,044 (27.1%) 0.6
  Level 6 5317 (6.1%) 13,347 (6.1%) 0.3
  Level 7 7066 (8.1%) 17,694 (8.1%) 0.2
  Level 8 24,079 (27.5%) 61,227 (28.1%) 1.4
Comorbidities
  PTSD 10,907 (12.4%) 25,465 (11.7%) 2.3
  TBI 108 (0.1%) 323 (0.1%) 0.7
  Ischemic stroke 1628 (1.9%) 5856 (2.7%) 5.6
  Stroke TIA 2255 (2.6%) 7460 (3.4%) 5.0
  Diabetes 18,497 (21.1%) 60,118 (27.6%) 15.2
  Addiction disorder 14,495 (16.5%) 43,358 (19.9%) 8.7
  Anxiety 7873 (9.0%) 17,391 (8.0%) 3.6
  Depressive disorder 15,349 (17.5%) 36,198 (16.6%) 2.4
  CHF 3213 (3.7%) 11,027 (5.1%) 6.8
  Schizophrenia 1738 (2.0%) 7848 (3.6%) 9.8
  COPD 7295 (8.3%) 22,389 (10.3%) 6.7
  Autoimmune disease 1460 (1.7%) 2975 (1.4%) 2.5
  Alcohol use disorder 4276 (4.9%) 13,247 (6.1%) 5.3
Care assessment needs score—average 1-year probability
  Mortality 3% 3% 6.5
  Hospitalization 16% 14% 11.0
  Any visit 17% 15% 9.2